Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Gilteritinib vs Midostaurin in Acute Myeloid Leukemia

Research Question:
How do gilteritinib and midostaurin compare in patients receiving standard combination chemotherapy for FLT3 acute Myeloid Leukemia?

Basic Study Information

Purpose:
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 65 will be randomly assigned to receive gilteritinib or midostaurin. Patients will also receive standard chemotherapy of daunorubicin and cytarabine. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML.

Location: University of Rochester Medical Center
Study Reference #: ILEU19039

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Sarah Rollinson
Phone: (585) 275-9485
Email: sarah_rollinson@urmc.rochester.edu

Additional Study Details

Return to Search